Post written by Don C. Codipilly, MD, from the Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.

Esophageal squamous cell carcinoma is well known worldwide for causing substantial morbidity and mortality. Our aim was to highlight recent advances in both endoscopic and non-endoscopic screening and surveillance strategies.

We felt clinicians would appreciate a review of the esophageal squamous cell cancer given its worldwide predilection. Given the considerable cost associated with endoscopic screening in conjunction with this cancer’s prevalence in developing nations, we felt it was important to highlight novel screening methods, including the use of non-invasive biomarkers that can potentially reduce morbidity in a cost-effective manner.

We provided a broad overview of the pertinent screening methods for esophageal squamous cell carcinoma. Our discussion highlighted the sensitivity and specificity of various endoscopic and non-endoscopic screening methods. We discussed several trials that showed the impact of screening programs on the general population in endemic regions. We also highlighted data from several promising biomarker studies.

Read the full article online.

The information presented in Endoscopedia reflects the opinions of the authors and does not represent the position of the American Society for Gastrointestinal Endoscopy (ASGE). ASGE expressly disclaims any warranties or guarantees, expressed or implied, and is not liable for damages of any kind in connection with the material, information, or procedures set forth.